WARPNINE Incorporated was established in May 2021 by Dr Andrew Dean, a leading West Australian Oncologist, who recognised the escalating need for dedicated research, greater awareness, and increased support for people and families impacted by pancreatic, gastro-intestinal and rare cancers.
More Australians die from pancreatic, gastro-intestinal and rare cancers each year than prostate and breast cancers combined. They have significantly worse prognosis and five-year survival rates.
​
Estimated numbers from 2023 show some of these heart-breaking statistics:
Number of people diagnosed with pancreatic cancer:
4,506
Number of people diagnosed with stomach and or oesophageal cancer:
4,301
Number of people diagnosed with rare or less common cancer:
52,000
% of all cancer deaths as a result of gastro-intestinal cancers:
73%
Source:
Data source: AIHW Cancer Data – Web report 2023 (Last updated: 31 Aug 2023
Forged from Philanthropy
WARPNINE started with an idea: a vision to significantly improve survival from pancreatic, gastro-intestinal, and rare cancers.
Brought to fruition through the generosity of our founding donors, we strive to raise critical funds enabling translational research from laboratory to bedside, clinical research with immediate relevant clinical trials, that have direct patient benefit and projects that improve both the short and long-term health and wellbeing of Western Australians.
Key Actions to Achieve our Objectives
We will:
Support revolutionary clinical trials that have direct patient benefit.
Raise awareness of pancreatic, gastro-intestinal, and rare cancers, and advocate for change to improve the inequalities in funding and research for these malignancies in an effort to support earlier diagnosis and improve patient outcomes.
Support research that has rapid, clinically meaningful benefit to patients.
Support future leaders to attract the best and brightest to the field of pancreatic,
gastro-intestinal, and rare cancer research.
Contribute to the discovery and implementation of innovative and individualised treatments and therapies to treat and reduce cancer recurrence.
Work to improve best practice in patient care to ensure the needs of patients and their families are met.
